Director, Portfolio Omnichannel (Lung HCP)
Revolution Medicines - Redwood City, California, United States
Posted May 20, 2026
Benefits
- Parental leave
- Not verified
- Non-birth-parent leave
- Not verified
- Family-building benefits
-
- Fertility benefits: Not verified
- Adoption assistance: Not verified
- Surrogacy assistance: Not verified
- Mental health support
- Not verified
- Relocation assistance
- Not verified
- Childcare support
- Not verified
- Learning budget
- Not verified
- Verification
- Not verified checked Jun 7, 2026
- Salary
- $211K-$264K From the posting source checked Jun 20, 2026
- 401(k) match
- Reported from DOL Form 5500 industry filing (not employer-specific)
Was this benefit information wrong? Tell us.
Market context
- U.S. role benchmark (BLS OEWS)
- $93,011 U.S. median for this role
- Projected growth (BLS Employment Projections)
- +5.1% - Faster than average
155% above the BLS role benchmark for marketing aggregate.
Matched to SOC 13-1161 - Marketing aggregate by role bucket.
Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.
Role
Schedule
- Shift type
- Not verified
- Weekend work
- Not verified
Company
Application
- Cover letter
- Not verified
- Assessment
- Not verified
- Deadline
- Not stated
Where they hire
State eligibility is not yet verified.
About this role
Director, Portfolio Omnichannel (Lung HCP) Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This newly created role represents a unique opportunity to shape the future of HCP engagement at Revolution Medicines. The Portfolio Omnichannel Strategy & Operations Team is seeking a forward-thinking, digitally fluent marketing operations leader to drive optimal performance while also delivering high-quality customer experiences across our HCP engagement channels. The Director, Portfolio Omnichannel Strategy & Operations (Oncology Lung HCP) is a highly collaborative leader focused on both strategy & execution and is responsible for partnering with Brand & Commercial function Leads in translating oncology brand strategies into high-impact, compliant, and innovative customer engagement experiences. This leader will define and socialize the strategy and approach to successfully pull through Lung's portfolio of customer engagement ambitions (aligned to the brand's strategic imperatives, objectives and key measures). In a fast-paced, growth-stage biotech environment, this role serves as the connector between strategy and execution partnering cross-functionally
Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.
Apply link not verified; last-live date unavailable.
What verified means
Verified means a displayed claim has field-level provenance to a source FewerJobs pulled: a government or employer source, or the original job posting. Posting-sourced facts are employer-stated and are labeled separately from government records.
Related jobs
-
Director, Product Management
Heartflow INC - San Francisco, California
-
Senior Director, Pharmaceutical Strategy and Development Leader
Crinetics Pharmaceuticals INC - San Diego, CA
-
Director, Pharmaceutical Development
Fulcrum Therapeutics INC - Cambridge, MA
-
Director, Data Management
Protara Therapeutics INC - New York, NY, Remote